ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DEMG Deltex Medical Group Plc

0.1025
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1025 0.10 0.105 0.1025 0.1025 0.1025 549,019 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electromedical Apparatus 2.48M -1.15M -0.0006 -1.67 1.85M

Deltex Medical Group PLC Half year trading update (5978R)

07/07/2022 7:00am

UK Regulatory


Deltex Medical (LSE:DEMG)
Historical Stock Chart


From Mar 2022 to Mar 2024

Click Here for more Deltex Medical Charts.

TIDMDEMG

RNS Number : 5978R

Deltex Medical Group PLC

07 July 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation

7 July 2022

Deltex Medical Group plc

("Deltex Medical" or the "Group")

Half year trading update

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring, today publishes an update on trading for the half-year ended 30 June 2022 ("H1 2022").

Revenues for the six months ended 30 June 2022 increased approximately 9% to GBP1.2 million unaudited (2021: GBP1.1 million).

Activity levels in the USA and UK during H1 2022 continued to be adversely impacted by Covid-19, with restricted access into hospitals' operating rooms and shortages of clinical staff causing disruption to elective surgery volumes. However, within our International division (which excludes the USA) we saw further revenue growth, as many of the health systems our distributors sell into continue to ease their Covid-19 restrictions.

The Board's expectation for the second half of 2022 is that the number of elective procedures in the UK and USA will increase and access into hospitals will improve for our teams of clinical educators and sales experts. This, along with the anticipated European launch of our next generation TrueVue monitor, which includes a novel non-invasive modality, later this year is expected to drive higher revenues.

Cash at hand on 30 June 2022 was GBP0.6 million (30 June 2021: GBP0.6 million).

Nigel Keen, Chairman of Deltex Medical, said:

"Given the subdued state of the Group's core elective surgery markets, combined with ongoing challenges associated with Deltex Medical's clinical educators gaining access to key accounts, we are pleased to see a return to growth in the first half."

"It is encouraging to see our international division continue to grow strongly and we expect growth to return in the UK and USA markets as Covid-related restrictions continue to ease."

"We are looking forward to the European release of the next generation TrueVue monitor, which we are aiming to launch later this year and expect to generate immediate capital replacement revenues from our distribution partners and enable better access to hospitals as clinicians evaluate this new technology."

For further information, please contact:

 
 Deltex Medical Group plc                   01243 774 837 
 Nigel Keen, Chairman                       investorinfo@Deltexmedical.com 
 Andy Mears, Chief Executive 
 Natalie Wettler, Group Finance Director 
 
 
 Nominated Adviser and Joint Broker 
  Allenby Capital Limited                      020 3328 5656 
 Jeremy Porter/ Vivek Bhardwaj (Corporate    info@allenbycapital.com 
  Finance) 
  Tony Quirke (Sales & Corporate Broking) 
 
 Joint Broker 
 Turner Pope Investments (TPI) Ltd           020 3657 0050 
 Andy Thacker                                info@turnerpope.com 
  James Pope 
 

Notes for Editors

Deltex Medical's technology

Deltex Medical's TrueVue System uses proprietary haemodynamic monitoring technology to assist clinicians to improve outcomes for patients as well as increase throughput and capacity for hospitals.

Deltex Medical has invested over the long term to build a unique body of peer-reviewed, published evidence from a substantial number of trials carried out around the world. These studies demonstrate statistically significant improvements in clinical outcomes providing benefits both to patients and to the hospital systems by increasing patient throughput and expanding hospital capacity.

The Group's flagship, world-leading, ultrasound-based oesophageal Doppler monitoring ("ODM") is supported by 24 randomised control trials conducted on anaesthetised patients. As a result, the primary application for ODM is focussed on guiding therapy for patients undergoing elective surgery.

During 2021, Deltex Medical's engineers and scientists carried out successful research in conjunction with the UK's National Physical Laboratory ("NPL"), which has enabled the Group's 'gold standard' ODM technology to be extended and developed so that it can be used completely non-invasively. This will significantly expand the application of Deltex Medical's technology to non-sedated patients. This new technological enhancement, which will be available on the new next generation monitor, will substantially increase the addressable market for the Group's haemodynamic monitoring technologies and is complementary to the long-established ODM evidence base.

Our new non-invasive technology has potential applications for use in a number of healthcare settings, including:

-- Accident & Emergency for the rapid triage of patients, including the detection and diagnosis of sepsis, an important capability for patients presenting with COVID-19 symptoms;

-- In general wards to help facilitate a real-time, data-driven treatment regime for patients whose condition might deteriorate rapidly; and

-- In critical care units to allow regular monitoring of patients post-surgery who are no longer sedated or intubated.

One of the key opportunities for the Group in 2022 is positioning this new, non-invasive technology for use throughout the hospital. Our haemodynamic monitoring technologies provide clinicians with beat-to-beat real-time information on a patient's circulating blood volume and heart function. This information is critical to enable clinicians to optimise both fluid and drug delivery to patients.

Our business model is to drive the recurring revenues associated with the sale of single-use disposable ODM probes which are used in the TrueVue System and to complement these revenues with a new incremental revenue stream to be derived from our new non-invasive technology.

Both the existing single-use ODM probe and the new, non-invasive device connect to the same, next generation monitor which is due for launch in 2022. Monitors are sold or, due to hospitals' often protracted procurement times for capital items, loaned in order to encourage faster adoption of our technology.

Deltex Medical's customers

The principal users of our products are currently anaesthetists working in a hospital's operating theatre and intensivists working in ICUs. This customer profile will change as our new non-invasive technology is adopted by the market. In the UK we sell directly to the NHS. In the USA we sell directly to more than 30 major hospitals that appreciate the value of our evidence-based approach to haemodynamic management. We also sell through distributors in more than 40 countries in the European Union, Asia and the Americas.

Deltex Medical's objective

To see the adoption of our next generation TrueVue System, comprising both minimally invasive and non-invasive technologies, as the standard of care in haemodynamic monitoring for all patients from new-born to adult, awake or anaesthetised, across all hospital settings globally.

For further information please go to www.deltexmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTSSUFWMEESEFW

(END) Dow Jones Newswires

July 07, 2022 02:00 ET (06:00 GMT)

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart

Your Recent History

Delayed Upgrade Clock